Research & Development
AMP 2021 meeting puts spotlight back on cancer
Seminars at AMP 2021 focused on technologies and techniques to help detect and profile tumors, with special emphasis on hard-to-detect cancer cells that remain in patients after treatment.
November 22, 2021
Grail builds case for multicancer blood test
The dataset included 2,414 samples (1,530 with cancer and 884 without cancer) in a substudy of its Circulating Cell-free Genome Atlas (CCGA) study, as well as data for 1,169 participants without cancer in its Breast Cancer Screening Cohort for the Development of Assays for Early Cancer Detection (STRIVE) study of screening mammography.
September 30, 2019
Page 1 of 1